Article
Employers and health plans can begin to take control of these specialty drug costs by following 7 steps outlined in a new report released today by Prime.
Rising costs and increased use of specialty drugs are placing a greater burden on people, their employers and their health plans. In fact, spending on high-cost specialty drugs used to treat complex diseases such as cancer increased more than 19% among members of pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) in 2012. That increase differs greatly from Prime's 0.9% drop in traditional (all non-specialty) drug spending in 2012. But the good news is employers and health plans can begin to take control of these specialty drug costs by following 7 steps outlined in a new report released today by Prime. The report, "Specialty: Today & Tomorrow," highlights Prime's specialty drug trend over the past year and recommends strategies that high-performing plans use to manage the steady rise in these costs.
"With the rising use of specialty drugs the days of 1% to 2% increases in annual drug spend are nearing an end," said Peter Wickersham, Prime's senior vice president of cost of care. "We are clearly entering a time of higher costs and plan sponsors who act now will be in the best position to assure quality care for their members while managing these high costs."
The 7 steps to success outlined in the report include:
Specialty drugs now account for 30% of total drug costs. Prime predicts that number to reach 50% of total drug spending by 2018. This means using pharmacy benefit tools and member engagement strategies to manage them effectively is important.
"We've found those plan sponsors that are best managing specialty costs have these seven things in common," said Duane Barnes, Prime's senior vice president of consumer delivery. "By deploying these steps and taking a comprehensive approach to understanding specialty costs, plans can both help their members access these important medicines and use them safely and effectively."
A copy of the specialty report is now available on Prime's website and short videos about each of the 7 steps can be found on Prime's YouTube channel. This new report is the first specialty-focused report published by Prime. It follows Prime's 2013 Drug Trend Insights infographic released in May. Visit the Industry Insights of Prime's website for more drug trend information.
SOURCE: Prime
Read more here: http://www.sacbee.com/2013/10/10/5810066/new-prime-therapeutics-report.html#storylink=cpy
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa